IP Verse

Combination Therapy Involving Antibodies Against Claudin 18.2 For Treatment Of Cancer - EP3791896

The patent EP3791896 was granted to Astellas Pharma on Jan 10, 2024. The application was originally filed on May 21, 2013 under application number EP20194625A. The patent is currently recorded with a legal status of "Revoked".

EP3791896

ASTELLAS PHARMA
Application Number
EP20194625A
Filing Date
May 21, 2013
Status
Revoked
May 23, 2025
Publication Date
Jan 10, 2024
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions (4)

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentativeOpposition Status

Get instant alerts for new oppositions and patent status changes

DR H ULRICH DORRIESOct 10, 2024DORRIESADMISSIBLE
DR H ULRICH DORRIESOct 10, 2024DORRIES, HANS ULRICH , DF-MP DORRIES FRANK-MOLNIA & POHLMANADMISSIBLE
DR STRAUSOct 10, 2024STRAUSADMISSIBLE
MAIWALDOct 8, 2024MAIWALDADMISSIBLE

Patent Citations (16) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication Number
DESCRIPTIONEP0338841
DESCRIPTIONUS2003118592
DESCRIPTIONUS2003133939
DESCRIPTIONWO0243478
DESCRIPTIONWO2004035607
DESCRIPTIONWO8704462
DESCRIPTIONWO8901036
OPPOSITIONEP3254695
OPPOSITIONWO2007059997
OPPOSITIONWO2008145338
OPPOSITIONWO2013174510
OTHEREP3254695
SEARCHUS2012020989
SEARCHWO2008145338
SEARCHWO2010009794
SEARCHWO2011090005

Non-Patent Literature (NPL) Citations (76) New

NPL citations refer to non-patent references such as research papers, articles, or other publications cited during examination or opposition phases.

Citation PhaseReference Text
DESCRIPTION- "Analysis, Results, And Future Prospective Of The Therapeutic Use Of Radiolabeled Antibody In Cancer Therapy", Monoclonal Antibodies For Cancer Detection And Therapy, Academic Press, (19850000), pages 303 - 16
DESCRIPTION- "Antibodies For Drug Delivery", HELLSTROM et al., Controlled Drug Delivery, Marcel Dekker, Inc., (19870000), pages 623 - 53
DESCRIPTION- "Antibody Carriers Of Cytotoxic Agents In Cancer Therapy: A Review", THORPE, Monoclonal Antibodies '84: Biological And Clinical Applications, (19850000), pages 475 - 506
DESCRIPTION- BIRD et al., Science, (19880000), vol. 242, pages 423 - 426
DESCRIPTION- FISCHER, R. et al., Biol. Chem., (19990000), vol. 380, pages 825 - 839
DESCRIPTION- GLENN E. MORRIS, Epitope Mapping Protocols (Methods in Molecular Biology, ISBN 089603-375-9
DESCRIPTION- HOLLIGER, P. et al., Proc. Natl. Acad. Sci. USA, (19930000), vol. 90, pages 6444 - 6448
DESCRIPTION- HUSTON et al., Proc. Natl. Acad. Sci. USA, (19880000), vol. 85, pages 5879 - 5883
DESCRIPTION- JONES, P. et al., Nature, (19860000), vol. 321, pages 522 - 525
DESCRIPTION- KRAUS et al., "Recombinant antibodies for cancer therapy", Methods in Molecular Biology series, ISBN 0-89603-918-8
DESCRIPTION- "Monoclonal Antibodies For Immunotargeting Of Drugs In Cancer Therapy", AMON et al., Monoclonal Antibodies And Cancer Therapy, Alan R. Liss, Inc., (19850000), pages 243 - 56
DESCRIPTION- NEDDLEMANWUNSCH, J. Mol. Biol., (19700000), vol. 48, page 443
DESCRIPTION- OLWYN M. R. WESTWOODFRANK C. HAY, "Epitope Mapping: A Practical Approach", Practical Approach Series, vol. 248
DESCRIPTION- PEARSONLIPMAN, Proc. Natl Acad. Sci. USA, (19880000), vol. 85, page 2444
DESCRIPTION- "Poljak, R.", Structure, (19940000), vol. 2, pages 1121 - 1123
DESCRIPTION- POLLOCK et al., J. Immunol. Meth., (19990000), vol. 231, pages 147 - 157
DESCRIPTION- QUEEN, C. et al., Proc. Natl. Acad. Sci. U. S. A., (19890000), vol. 86, pages 10029 - 10033
DESCRIPTION- RIECHMANN, L. et al., Nature, (19980000), vol. 332, pages 323 - 327
DESCRIPTION- ROSSI et al., Am. J. Clin. Pathol., (20050000), vol. 124, page 295
DESCRIPTION- SCATCHARD et al., Ann N.Y. Acad. ScL, (19490000), vol. 51, page 660
DESCRIPTION- SMITHWATERMAN, Ads App. Math., (19810000), vol. 2, page 482
DESCRIPTION- SPIEKER-POLET et al., Proc. Natl. Acad. Sci. U.S.A., (19950000), vol. 92, page 9348
DESCRIPTION- VERMA, R. et al., J. Immunol. Meth., (19980000), vol. 216, pages 165 - 181
DESCRIPTION- WARD et al., Nature, (19890000), vol. 341, pages 544 - 546
DESCRIPTION- ZITVOGEL L. et al., Cell, (20100000), vol. 140, pages 798 - 804
DESCRIPTION- THORPE et al., "The Preparation And Cytotoxic Properties Of Antibody-Toxin Conjugates", Immunol. Rev., (19820000), vol. 62, doi:10.1111/j.1600-065X.1982.tb00392.x, pages 119 - 58, XP001179872
OPPOSITION- Anonymous, "P56856 · CLD18_HUMAN", UNIPROTKB, (20000530), Database accession no. 3P56856, XP093232994
OPPOSITION- Anonymous, "Safety and Tolerability Study of Claudiximab in Patients With Advanced Gastroesophageal Cancer", ClinicalTrials.gov; NCT00909025, (20170630), ClinicalTrials.gov; NCT00909025, URL: https://clinicaltrials.gov/study/NCT00909025?term=NCT00909025&rank=1&a=11, XP093233001
OPPOSITION- Anonymous Xiao Jun, Qiu Feng, Xiong Jian Ping, Zhang Ling, Yu Feng, Feng Miao, Zhan Zheng Yu, "A Phase II Trial of Epirubicin, Oxaliplatin, and Capecitabine (EOX) as First-Line Chemotherapy in Advanced Gastric Cancer: A Chinese Single-Center Experience | Chemotherapy | Karger Publishers", Karger - CHE, (20100101), Database accession no. 56/3/171/66736, XP093234745
OPPOSITION- Butt Waseem, Saadati Hamid, Saif Muhammad Wasif, "Oxaliplatin-induced Pancreatitis: A Case Series", ANTICANCER RESEARCH, (20101115), vol. 30, pages 5113 - 5116, XP093224802
OPPOSITION- "Carmustine", Wikipedia, (20230129), Wikipedia, URL: https://en.wikipedia.org/wiki/Carmustine, XP093224792
OPPOSITION- D10 - Submission filed during examination proceedings on February 17, 2022 of EP 20194625
OPPOSITION- D11 - Communication issued by the examining division dated May 11, 2022 The examination carried out on EP 20194625
OPPOSITION- D12 - Experimental Data - Chemotherapy treatment of NUGC-4 cells, Patu 8988s cells and BxPC3 cells
OPPOSITION- D13 - Materials and methods Treatment of tumor cell lines with stress-inducing agents - for D12
OPPOSITION- D23 - Opponent’s Experimental Report - Cldnl8.2 expression over cell cultivation period without chemotherapeutic agents
OPPOSITION- D37 - Information from ClinicalTrials.gov concerning the publication date of D36, specificallv the date "First Posted"
OPPOSITION- D39 - Opposition arguments of Dörries-dfmp
OPPOSITION- D40 - Appeal arguments of Dörries-dfmp
OPPOSITION- D6 - EP 17171169 A - Interlocutory decision in opposition proceedings (Art. 101(3)(a) and 106(2) EPC)
OPPOSITION- Debraud F., Munzone E., Nolè F., De Pas T., Biffi R., Brienza S., Aapro M. S., "Synergistic activity of oxaliplatin and 5-fluorouracil in patients with metastatic colorectal cancer with progressive disease while on or after 5-fluorouracil ", PubMed, (19980601), Database accession no. 9626798 , URL: NCBI, XP093234721
OPPOSITION- Eichhorst S T, Müerköster S., Weigand M.A., Krammer P.H. , "The Chemotherapeutic Drug 5-Fluorouracil Induces Apoptosis in Mouse Thymocytes in Vivo via Activation of the CD95(APO-1/Fas) System", Cancer Research, (20010101), vol. 61, pages 243 - 248, XP093091618
OPPOSITION- "Etoposide", Wikipedia, (20230128), Wikipedia, XP093224796
OPPOSITION- Felice Pasini, Anna Paola Fraccon, Giovanni De Manzoni, "The Role of Chemotherapy in Metastatic Gastric Cancer", Anticancer Research, (20111001), vol. 31, no. 10, pages 3543 - 3554, XP055819153
OPPOSITION- Fresenius Kabi, " LEUCOVORIN CALCIUM - leucovorin calcium injection - package insert", (20181101), pages 1 - 11, XP093229251
OPPOSITION- "Gastrointestinale Tumoren: Irinotecan erhöht die Chance, länger und besser zu überleben - Ergebnisse aus aktuellen klinischen Prüfungen", Clinical Investigators Update Meeting on Gastro-Intestinal Cancer - Beilage zu ONKOLOGIE, Band 25, Heft 3, Juni 2002, (20020420), vol. 25, pages 1 - 4, XP093230680
OPPOSITION- Jacobs C, Lyman G, Velez-García E, Sridhar K S, Knight W, Hochster H, Goodnough L T, Mortimer J E, Einhorn L H, Schacter L, "A phase III randomized study comparing cisplatin and fluorouracil as single agents and in combination for advanced squamous cell carcinoma of the head and neck", PubMed, (19920201), Database accession no. 1732427 , URL: NCBI, XP093234727
OPPOSITION- Michael Andreeff, Dietmar P. Berger, Benjamín Koziner, Monika Engelhardt, Hans A. Messner, Hartmut Henß, N. Thatcher, and Roland Mertelsmann, "Part 4 - Supportive Care - 4.7 - Bisphosphonates", Michael Andreeff, Dietmar P. Berger, Benjamín Koziner, Monika Engelhardt, Hans A. Messner, Hartmut Henß, N. Thatcher, and Roland Mertelsmann, Berger, Dietmar Paul, Andreeff, Michael, Concise manual of hematology and oncology : with 474 tables, DE, Berlin ; Heidelberg [u.a.] : Springer, (20080609), pages 528 - 780, ISBN 978-3-540-73276-1, XP009558580
OPPOSITION- Sulkes A, Smyth J, Sessa C, Dirix L Y, Vermorken J B, Kaye S, Wanders J, Franklin H, Lebail N, Verweij J, "Docetaxel (Taxotere) in advanced gastric cancer: results of a phase II clinical trial", Br Journal Cancer, (19940101), vol. 70, pages 380 - 383, XP093091440
OPPOSITION- Thierry André, Boni Corrado, Mounedji-Boudiaf Lamia, Navarro Matilde, Tabernero Josep, Hickish Tamas, Topham Clare, Zaninelli Marta, Clingan Philip, Bridgewater John, Tabah-Fisch Isabelle, De Gramont Aimery, "Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer", PubMed, (20040603), Database accession no. 15175436 , URL: NCBI, XP093234711
OPPOSITION- Van Cutsem E, Blijham G H, "Irinotecan versus infusional 5-fluorouracil: a phase III study in metastatic colorectal cancer following failure on first-line 5-fluorouracil. V302 Study Group", PubMed, (19990226), Database accession no. 10213010, URL: NCBI, XP093234706
OPPOSITION- VELDERS M P, ET AL., "THE IMPACT OF ANTIGEN DENSITY AND ANTIBODY AFFINITY ON ANTIBODY-DEPENDENT CELLULAR CYTOTOXICITY: RELEVANCE FOR IMMUNOTHERAPY OF CARCINOMAS", British Journal of Cancer, GB, (19980801), vol. 78, no. 04, ISSN 0007-0920, pages 478 - 483, XP009027871
OPPOSITION- Hirotake Tokuyama; Tomomi Hagi; Stephen R. Mattarollo; Jacqueline Morley; Qiao Wang; Hang Fai‐So; Fuminori Moriyasu; Mie Nieda; Andrew J. Nicol, "Vγ9Vδ2 T cell cytotoxicity against tumor cells is enhanced by monoclonal antibody drugs—Rituximab and trastuzumab", International Journal of Cancer, US , (20080228), vol. 122, no. 11, doi:10.1002/ijc.23365, ISSN 0020-7136, pages 2526 - 2534, XP071285149
OPPOSITION- Muñoz‐sánchez Jorge, Chánez‐cárdenas María E., "The use of cobalt chloride as a chemical hypoxia model", Journal of Applied Toxicology, GB , (20190401), vol. 39, no. 4, doi:10.1002/jat.3749, ISSN 0260-437X, pages 556 - 570, XP093091472
OPPOSITION- Beverly A. Teicher, "Tumor Models in Cancer Research Second Edition /Passage/", Tumor Models in Cancer Research Second Edition, Springer Science+Business Media, LLC , (20110101), pages 106 - 598, doi:10.1007/978-1-60761-968-0, XP055819148
OPPOSITION- Sahin U., Türeci Ö., Manikhas G., Lordick F., Rusyn A., Vynnychenko I., Dudov A., Bazin I., Bondarenko I., Melichar B., Dhaene K., Wiechen K., Huber C., Maurus D., Arozullah A., Park J.W., Schuler M., Al-Batran S.-E., "FAST: a randomised phase II study of zolbetuximab (IMAB362) plus EOX versus EOX alone for first-line treatment of advanced CLDN18.2-positive gastric and gastro-oesophageal adenocarcinoma", Annals of Oncology, (20210501), vol. 32, no. 5, doi:10.1016/j.annonc.2021.02.005, ISSN 0923-7534, pages 609 - 619, XP093116419
OPPOSITION- de Gramont, A. Vignoud, J. Tournigand, C. Louvet, C. Andre, T. Varette, C. Raymond, E. Moreau, S. Le Bail, N. Krulik, M., "Oxaliplatin with High-dose Leucovorin and 5-Fluorouracil 48-hour Continuous Infusion in Pretreated Metastatic Colorectal Cancer", European Journal of Cancer, Elsevier, 34th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics, Barcelona, Spain, 34th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics, Barcelona, Spain, (19970201), vol. 33, no. 2, doi:10.1016/S0959-8049(96)00370-X, ISSN 0959-8049, pages 214 - 219, XP004282501
OPPOSITION- Schønnemann K R, Jensen H A, Yilmaz M, Jensen B V, Larsen O, Pfeiffer P, "Phase II study of short-time oxaliplatin, capecitabine and epirubicin (EXE) as first-line therapy in patients with non-resectable gastric cancer", British Journal of Cancer, GB, (20080901), vol. 99, no. 6, doi:10.1038/sj.bjc.6604569, ISSN 0007-0920, pages 858 - 861, XP093230685
OPPOSITION- Shaulian Eitan; Karin Michael, "AP-1 in cell proliferation and survival", Oncogene, GB, (20010430), vol. 20, no. 19, doi:10.1038/sj.onc.1204383, ISSN 0950-9232, pages 2390 - 2400, XP037732227
OPPOSITION- Roti Roti Joseph L, "Cellular responses to hyperthermia (40-46 degrees C): cell killing and molecular events", INTERNATIONAL JOURNAL OF HYPERTHERMIA, GB , (20080201), vol. 24, no. 1, doi:10.1080/02656730701769841, ISSN 0265-6736, pages 3 - 15, XP009167442
OPPOSITION- Özlem Türeci, Mitnacht-Kraus Rita, Wöll Stefan, Yamada Tomohiro, Sahin Ugur, "Characterization of zolbetuximab in pancreatic cancer models", Oncoimmunolgy, US , (20190102), vol. 8, no. 1, doi:10.1080/2162402X.2018.1523096, ISSN 2162-4011, page e1523096, XP055678806
OPPOSITION- DUCREUX M ET AL, "Randomized phase II study evaluating oxaliplatin alone, oxaliplatin combined with infusional 5-FU, and infusional 5-FU alone in advanced pancreatic carcinoma patients.", Annals of Oncology, (20040301), vol. 15, no. 3, doi:10.1093/annonc/mdh098, pages 467 - 473, XP002420489
OPPOSITION- EICHHORST SOEREN T ET AL, "A novel AP-1 element in the CD95 ligand promoter is required for induction of apoptosis in hepatocellular carcinoma cells upon treatment with anticancer drugs.", MOLECULAR AND CELLULAR BIOLOGY, US , (20001001), vol. 20, no. 20, doi:10.1128/MCB.20.20.7826-7837.2000, ISSN 0270-7306, pages 7826 - 7837, XP002194897
OPPOSITION- Allum W. H., Blazeby J. M., Griffin S. M., Cunningham D., Jankowski J. A., Wong R., "Guidelines for the management of oesophageal and gastric cancer", Gut microbiota, British medical association, GB, (20111101), vol. 60, no. 11, doi:10.1136/gut.2010.228254, ISSN 0017-5749, pages 1449 - 1472, XP093091551
OPPOSITION- Yano Koichi, Imaeda Takashi, Niimi Tomoaki, "Transcriptional activation of the human claudin-18 gene promoter through two AP-1 motifs in PMA-stimulated MKN45 gastric cancer cells", American Journal of Physiology - Gastrointestinal and Liver Physiology, US , (20071114), vol. 294, no. 1, doi:10.1152/ajpgi.00328.2007, ISSN 0193-1857, pages G336 - G343, XP093091614
OPPOSITION- Niwa R; Sakurada M; Kobayashi Y; Uehara A; Matsushima K; Ueda R; Nakamura K; Shitara K, "Enhanced natural killer cell binding and activation by low-fucose IgG1 antibody results in potent antibody-dependent cellular cytotoxicity induction at lower antigen density", Clinical Cancer Research, US, (20050315), vol. 11, no. 6, doi:10.1158/1078-0432.CCR-04-2263, ISSN 1078-0432, pages 2327 - 2336, XP009144270
OPPOSITION- Ugur Sahin, Michael Koslowski, Karl Dhaene, Dirk Usener, Gunda Brandenburg, Gerhard Seitz, Christoph Huber , Özlem Türeci, "Claudin-18 splice variant 2 is a pan-cancer target suitable for therapeutic antibody development.", Clinical Cancer Research, US, (20081201), vol. 14, no. 23, doi:10.1158/1078-0432.CCR-08-1547, ISSN 1078-0432, pages 7624 - 7634, XP002588324
OPPOSITION- Omura Kenji, "Advances in Chemotherapy against Advanced or Metastatic Colorectal Cancer", DIGESTION, S. Karger AG., CH , (20080101), vol. 77, no. Suppl. 1, doi:10.1159/000111483, ISSN 0012-2823, pages 13 - 22, XP093229256
OPPOSITION- Tetzlaff Eric, Ajani Jaffer, Cheng Jonathan, "Review of docetaxel in the treatment of gastric cancer", Therapeutics and Clinical Risk Management, (20081001), vol. 4, no. 5, doi:10.2147/TCRM.S3226, pages 999 - 1007, XP055819157
OPPOSITION- Kontermann R E, "Strategies to extend plasma half-lives of recombinant antibodies", BIODRUGS, NZ , (20090401), vol. 23, no. 2, doi:10.2165/00063030-200923020-00003, ISSN 1173-8804, pages 93 - 109, XP008124089
OPPOSITION- Sastre Javier, García-Saenz Jose Angel, Díaz-Rubio Eduardo, "Chemotherapy for gastric cancer", World Journal of Gastroenterology, CN , (20060101), vol. 12, no. 2, doi:10.3748/wjg.v12.i2.204, ISSN 1007-9327, pages 204 - 213, XP093091466
OPPOSITION- Bagnyukova Tetyana V., Serebriiskii Ilya G., Zhou Yan, Hopper-Borge Elizabeth A., Golemis Erica A., Astsaturov Igor, "Chemotherapy and signaling : How can targeted therapies supercharge cytotoxic agents?", Cancer biology & therapy, US , (20101101), vol. 10, no. 9, doi:10.4161/cbt.10.9.13738, ISSN 1538-4047, pages 839 - 853, XP093091620
SEARCH- Aristides Polyzos ET AL, "Subsets of Patients with Advanced Gastric Cancer Responding to Second-line Chemotherapy with Docetaxel - Cisplatin", Anticancer Research, Greece, (20060901), pages 3749 - 3754, URL: http://ar.iiarjournals.org/content/26/5B/3749.full.pdf#page=1&view=FitH, (20200114), XP055657695 [T] * the whole document *
SEARCH- Ganymed Pharmaceuticals Gmbh, "Safety and Tolerability Study of Claudiximab in Patients With Advanced Gastroesophageal CancerNCT00909025", ClinicalTrials.gov, (20090327), URL: http://citenpl.internal.epo.org/wf/web/citenpl/citenpl.html, (20181115), XP055524253 [A] 1-14 * the whole document *
SEARCH- KOBUNAI TAKASHI ET AL, "Antitumour Activity of S-1 in Combination with Cetuximab on Human Gastric Cancer Cell Lines In Vivo", ANTICANCER RESEARCH, (201111), vol. 31, no. 11, pages 3691 - 3696, XP002678607 [A] 1-14 * the whole document *
SEARCH- SAHIN UGUR ET AL, "Claudin-18 splice variant 2 is a pan-cancer target suitable for therapeutic antibody development", CLINICAL CANCER RESEARCH, AMERICAN ASSOCIATION FOR CANCER RESEARCH, US, (20081201), vol. 14, no. 23, doi:10.1158/1078-0432.CCR-08-1547, ISSN 1078-0432, pages 7624 - 7634, XP002588324 [A] 1-14 * the whole document *

Download Citation Report

Get a free citation report including examiner, opposition, and international search citations.

Get Citation Report

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents